PR.com: Business Directory, Press Releases, Jobs, Products, Services, Articles
 
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | PR.com News on Your Site
 

Press Releases

 
AbboMax, Inc.

Press Release


Receive press releases from AbboMax, Inc.: By Email RSS Feeds:

Scientists at AbboMax Developed Antibodies Against PINK1 and Parkin to Study Parkinson’s Disease


A panel of PINK1 and Parkin antibodies was developed at Abbomax to investigate Parkinson’s disease (PD). These phosphospecific and paired antibodies would be useful tools for studies of PINK/Parkin pathways and signaling in PD. AbboMax has been developing & manufacturing high performance immunoassay reagents for many years in California. AbboMax specializes in high-quality custom service and products focusing on antibody and assay development.

San Jose, CA, May 09, 2019 --(PR.com)-- A panel of PINK1 and Parkin antibodies was developed at Abbomax to investigate Parkinson’s disease. Parkinson's disease (PD) is a long-term neurodegenerative disease caused by the progressive degeneration of the dopaminergic neurons of the substantia nigra pars compacta. It is associated with a pathological process involving metabolism deregulation, protein misfolding, mitochondrial dysfunction, and neuroinflammation. PINK1 and Parkin are two genes involved in familial forms of PD through the general mechanism. PINK1 (PTEN-induced putative kinase 1, a mitochondrial kinase) and Parkin (a ubiquitin ligase) play important roles in mitochondrial quality control. PINK1provides protection against mitochondrial dysfunction during cellular stress by phosphorylating mitochondrial proteins, and is involved in the clearance of damaged mitochondria. The phosphorylation of Parkin at Ser65 in ubiquitin-like domain by PINK1 stimulates Parkin activation and translocation to damaged mitochondria where it recruits Parkin to target the organelle for degradation through autophagy. Mutations in the PINK1 protein have been shown to lead to a build-up improperly folded proteins in the mitochondria. Mutations in the serine/threonine kinase domain have been found in a number of Parkinson's patients where PINK1 fails to protect against stress-induced mitochondrial dysfunction. In our study PINK1 and Parkin were found widely expressed in nervous systems and other organs. These phosphospecific and paired antibodies would be useful tools for studies of PINK/Parkin pathways and signaling in PD. AbboMax offers: Phosphospecific PINK1 (pT257) (#630-450), Phosphospecific Parkin (pS65) (#630-420); Paired PINK1 (T257) (#630-460), Paired Parkin (S65) (#630-430); Whole protein: PINK1 (#630-470) and Parkin (#630-440).

AbboMax has been involved in researching, developing and manufacturing of high performance antibodies and related immunoassay reagents for many years. Abbomax specializes in antibody and assay development, provides high-quality custom service and products. AbboMax is focusing on phosphospecific antibodies, IHC grade monoclonal antibodies, FFPE cell pellets slides, tissue/cell blocks and CRO services including recombinant protein, custom bio-conjugation, antibody fragmentation, Antibody Epitope Mapping (AEM), scale-up process for pharmaceutical companies and CLIA labs. All the manufacturing activities are performed in the Silicon Valley Core Facility located in San Jose, California. Abbomax can provide bulk quantities at economical prices, and guarantee a fast delivery with high quality products.

Contact: Natasha Raysberg, Ph.D.
Phone 408-573-1898, Fax 408-573-1858
Contact Information
AbboMax, Inc.
Natasha Raysberg
408-573-1898
Contact
www.abbomax.com

Click here to view the list of recent Press Releases from AbboMax, Inc.
Promote Your Business